Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 22, 2022 - Issue 12: Biological therapies for psoriasis
Submit an article Journal homepage
1,321
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?

Rohan Singha Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6532-1639View further author information
ORCID Icon,
Alexandria M Browna Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USAView further author information
,
Warren H Chana Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USAView further author information
,
Morgan A Farra Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USAView further author information
,
Sid Venkataramana Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USAView further author information
&
Steven R Feldmana Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA;b Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA;c Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USAView further author information
Pages 1439-1441 | Received 06 Jan 2022, Accepted 07 Jun 2022, Published online: 13 Jun 2022

References

  • Singh R, Koppu S, Perche PO, et al. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021Nov26;22(23):12793. PMID: 34884596; PMCID: PMC8657643.
  • Bellinato F, Gisondi P, Girolomoni G. Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules. Biologics. 2021Jun29;15:247–253. PMID: 34239295; PMCID: PMC8258237.
  • Vecellio M, Hake VX, Davidson C, et al. The IL-17/IL-23 axis and its genetic contribution to psoriatic arthritis. Front Immunol. 2021 Jan 7;11:596086. PMID: 33574815; PMCID: PMC7871349.
  • Tiwari V, Brent LH. Psoriatic Arthritis. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547710.
  • Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012Jul1;18(7):1069–1076. PMID: 22772566.
  • McInnes L, Mease P, Hjuler K, et al. Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and −2 trials. J Am Acad Dermatol. 2019 Oct;81(4):AB28.
  • Mease PJ, Chohan S, Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021Sep;80(9):1147–1157. Epub 2021 May 13. PMID: 33985942; PMCID: PMC8372392
  • Mease PJ, Helliwell PS, Hjuler KF, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2021Feb;80(2):185–193. Epub 2020 Oct 26. PMID: 33106286; PMCID: PMC7815636
  • Ward M, Maliyar K, Gooderham M. A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors. SAGE Open Med Case Rep. 2021Sep3;9:2050313X211034925. PMID: 34504710; PMCID: PMC8422814.
  • Ismail FF, May J, Moi J, et al. Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment. Dermatol Ther. 2020Mar;33(2):e13216. Epub 2020 Jan 8. PMID: 31899569.
  • Singh I, Uy A, Kassardjian A, et al. Brodalumab in an organ transplant recipient with psoriasis. Cutis. 2021Feb;107(2):104–106. PMID: 33891842.
  • Rivera-Oyola R, Stanger R, Litchman GH, et al. The Use of brodalumab in three patients with psoriasis and psychiatric comorbidities. J Clin Aesthet Dermatol. 2020Dec; 1312: 44–48. Epub 2020 Dec 1. PMID: 33488920; PMCID: PMC7819587
  • Pinter A, Bonnekoh B, Hadshiew IM, et al. Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. Clin Cosmet Investig Dermatol. 2019Jul10;12:509–517. PMID: 31372022; PMCID: PMC6628099.
  • Horton DB, Blum MD, Burcu M. Real-world evidence for assessing treatment effectiveness and safety in pediatric populations. J Pediatr. 2021Nov; 238: 312–316. Epub 2021 Jul 2. PMID: 34217767; PMCID: PMC8249672
  • Ruggiero A, Fabbrocini G, Cinelli E, et al. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022Mar;473:561–567. Epub 2021 Nov 17. PMID: 34642965
  • Ruggiero A, Fabbrocini G, Cinelli E, et al. Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021Oct;85(4):1028–1030. Epub 2021 Mar 21. PMID: 33762130.
  • Ruggiero A, Fabbrocini G, Cinelli E, et al. Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study. Dermatol Ther. 2022Jan;35(1):e15214. Epub 2021 Nov 30. PMID: 34800070.
  • Chan WH, Singh R, Feldman SR. Should the presence of psoriatic arthritis change how we manage psoriasis? J Dermatolog Treat. 2021Dec;32(8):863–865. PMID: 34515604.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.